Tonix Pharmaceuticals stock halted ahead of FDA approval news
Celestica Inc. (CLS) stock reached an all-time high of 216.54 USD, marking a significant milestone for the $24.57 billion technology company. According to InvestingPro data, the company maintains a "GREAT" financial health score, though current technical indicators suggest the stock may be in overbought territory. Over the past year, Celestica’s stock has experienced a remarkable increase of 308.36%, reflecting strong investor confidence and positive market performance. With revenue growth of 20.52% and strong returns across multiple timeframes, this surge underscores the company’s robust growth trajectory and its ability to capitalize on market opportunities, propelling its stock to unprecedented levels. As Celestica continues to expand its operations and innovate within the tech industry, investors remain optimistic about its future prospects. For deeper insights and additional analysis, including 22 actionable ProTips, explore the comprehensive research report available on InvestingPro.
In other recent news, Celestica has reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company posted an adjusted earnings per share of $1.39, exceeding the forecasted $1.23, and achieved revenue of $2.89 billion, which was 8.24% higher than anticipated. Following these results, Celestica has revised its full-year guidance upward, now projecting revenue of $11.55 billion and an adjusted EPS of $5.50. In response to the robust demand from hyperscalers, RBC Capital raised its price target for Celestica to $225 while maintaining an Outperform rating. Similarly, Stifel increased its price target to $230 from $150, citing strong AI demand and maintaining a Buy rating. In corporate developments, Celestica announced the appointment of Chris Colpitts to its Board of Directors, expanding the board to nine members. Colpitts brings 20 years of experience in the technology, media, and telecommunications sectors. These developments reflect a period of positive momentum for Celestica.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.